Classes
DEA Class; Discontinued
Common Brand Names; Ticlid
- Antiplatelet Agents, Cardiovascular;
- Antiplatelet Agents, Hematologic
Description
Oral platelet-aggregation inhibitor; associated with a risk of life-threatening blood dyscrasias; should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.
Indications
Indicated for arterial thromboembolism prophylaxis (e.g., stroke prophylaxis) to reduce the risk of sustaining an initial (fatal or nonfatal) thrombotic stroke after a transient ischemic attack (TIA) or to reduce the risk of recurrent thrombotic stroke in patients who have sustained a completed thrombotic stroke.
For subacute coronary thrombosis prophylaxis (i.e., abrupt closure) in combination with aspirin in recipients of a coronary artery stent following percutaneous coronary intervention (PCI).
Contraindications
Documented hypersensitivity
Neutropenia, thrombocytopenia, hemostatic disorder or active bleeding (GI bleed, ICH), severe hepatic impairment, history of either thrombotic thrombocytopenic purpura (TTP) or aplastic anemia
Current use of other anticoagulant drugs
Adverse Effects
- Diarrhea (12.5%)
- Elevated alkaline phosphatase (7.6%)
- Nausea (7%)
- Dyspepsia (7%)
- Rash (5%)
- GI pain (3.7%)
- Elevated AST/SGOT (3.1%)
- Neutropenia (2.4%)
- Purpura (2.2%)
- Vomiting (1.9%)
- Flatulence (1.5%)
- Pruritus (1.3%)
- Dizziness (1%)
- Abnormal LFTs (1%)
- Anorexia (1%)
- Agranulocytosis
- Aplastic anemia
- Pancytopenia
- TTP
Warnings
Due to risk of adverse hematologic events, for stroke prevention use only in ASA-intolerant patients
Patients with lesions that have a propensity to bleed
Discontinue 10-14 days before elective major surgery in patients with bleeding diathesis
Increases serum chlesterol & triglyceride concentrations
Long-term use with concurrent aspirin not recommended
Pregnancy and Lactation
Pregnancy Category: B
Lactation: not known whether excreted in breast milk, discontinue drug or do not nurse
Maximum Dosage
500 mg/day PO.
500 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Ticlopidine hydrochloride
Discontinued